Alpha-Lipoic Acid dosage

Protocol

1. 1

   Measure the dose

   Typical Alpha-Lipoic Acid dose is 600 mg (300 to 600 mg/day for general metabolic use; 600 to 1800 mg/day for diabetic neuropathy; R-ALA dosed at 100 to 300 mg/day). Use a weight-based calculator for individual adjustments.

   Open tool →
2. 2

   Set the frequency

   Administer 1 to 3 times daily on empty stomach. Half-life of 0.5 hours anchors the dosing interval.

   Open tool →
3. 3

   Cycle if needed

   No cycling required for typical use; some users pulse 12 weeks on / 4 weeks off

   Open tool →
4. 4

   Monitor for side effects

   Watch for: nausea; abdominal discomfort; diarrhea; sulfurous odor. Stop or reduce dose if tolerability breaks down.

Why this dose

Dual lipid- and water-soluble antioxidant; redox cycles with dihydrolipoic acid (DHLA) to scavenge ROS, regenerate vitamin E and C, and chelate transition metals. Activates AMPK in liver and muscle; cofactor for pyruvate and alpha-ketoglutarate dehydrogenase complexes.

The typical dose (600 mg) reflects 300 to 600 mg/day for general metabolic use; 600 to 1800 mg/day for diabetic neuropathy; R-ALA dosed at 100 to 300 mg/day. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

Alpha-Lipoic Acid is administered via the oral or iv routes. Oral dosing is straightforward: take with water, with or without food unless specifically noted.

Onset of action runs around 30 minutes after administration. Peak effect lands near 1 hour post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Plasma half-life ~30 minutes; oral bioavailability 30 to 40% racemic, 40 to 60% R-ALA; food reduces absorption substantially

Cycling and tolerance

No cycling required for typical use; some users pulse 12 weeks on / 4 weeks off

Effects to expect at typical dose

• Approved Rx for diabetic neuropathy in Germany at 600 mg/day IV (Thioctacid) since 1960s
• Improves neuropathy symptoms (TSS, NIS) at 600 mg/day IV across ALADIN and SYDNEY trials
• R-ALA enantiomer absorbs 40-100% better than racemic mixtures
• Activates AMPK; produces small HbA1c reductions in T2DM
• Plasma half-life ~30 minutes; split dosing or sustained-release is standard
• Hypoglycemia risk with insulin or sulfonylureas; medication adjustment may be required

Side effects and interactions

Common side effects

• nausea
• abdominal discomfort
• diarrhea
• sulfurous odor
• rash (rare)

Notable interactions

• insulin and sulfonylureas (major): additive hypoglycemia; medication dose adjustment may be required
• thyroid hormone (moderate): may reduce T4 to T3 conversion at high doses
• iron supplements (moderate): ALA chelates iron and reduces absorption; separate dosing
• chemotherapy (oxidative-stress-dependent agents) (moderate): theoretical interference; coordinate with oncology team
• biotin (minor): ALA competes with biotin uptake; chronic use can induce biotin insufficiency

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Alpha-Lipoic Acid profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

allowed

DEA / Rx

Not scheduled

Pregnancy

Insufficient data; precautionary avoidance

Legal status

Dietary supplement (US, UK, Canada, most EU); prescription drug for diabetic neuropathy in Germany

Do not use if

• pregnancy and lactation (insufficient safety data)
• active insulin autoimmune syndrome predisposition

Related research